How is a beyond-use date set for a compounded multi-dose vial?

Costs, fees and monitoring all included, I am trying to compare like with like.

I can find plenty of assertions about this and almost no reasoning, which is usually a sign that nobody has checked.

Assume no laboratory access beyond what I can pay a third party for.

So: what is the actual procedure, and which steps matter as opposed to being ritual?

Mechanically, salt forms and additives are the usual point of divergence and are worth asking about specifically.

Compounding is the preparation of a medicine for an individual patient in response to a prescription, where an approved product is unsuitable. It sits outside the approval framework by design rather than by omission.

Regulators generally prohibit compounding what is essentially a copy of a commercially available product, with a shortage listing being the usual exception that permits it temporarily.

Compounding is defined in regulation as preparation for an individual patient under prescription and is distinguished from manufacturing by scale and by the patient-specific requirement.

The framework is jurisdiction-specific. Check yours rather than a general answer.

Start with the regulatory basis, because compounding is permitted under specific conditions and those conditions are the whole subject.

Salt forms matter: a compounded preparation using a different salt from the approved product is not the same active moiety, and that has been the specific object of regulatory warnings.

Ask for the certificate of analysis on the compounded lot. A serious facility will have one; the request itself is informative.

Check the beyond-use date and what it was based on.

The underlying point is that the relevant distinction is between compounding for an individual patient and compounding at scale, which are regulated differently.

Additives are the other divergence. Preparations combining an active with vitamins or other agents are not equivalent to the approved product and have not been studied in that combination.

Beyond-use dates on compounded sterile preparations are set by standards that depend on the preparation environment and are much shorter than a manufactured product's shelf life.

Regulatory warnings have specifically addressed salt forms differing from the approved active moiety in this therapeutic area.

Ask which salt form. A different salt is a different active moiety.

edited 9 Feb 2026 by halvard_ness — corrected a unit error in the worked example

Stated carefully, this is an area where the legal position and the quality question are separate and both matter.

A compounded preparation has no marketing authorisation, no batch release by a qualified person and no pharmacovigilance obligation attached to it. That is the structural difference from a licensed product.

Prohibitions on compounding essential copies of commercially available products are explicit in the relevant regulatory frameworks, with shortage listings as the usual exception.

The caveat is that the legal and regulatory position differs by jurisdiction and nothing here is legal advice.

Compounded means unapproved by definition. That is structural, not pejorative.

edited 10 Jan 2026 by ines_brandt — added a caveat about sampling

The honest answer is that a well-run compounding pharmacy is a serious operation and that the variance across facilities is wide.

Facility quality varies enormously and is the practical determinant of what you receive. The relevant questions are about sterility assurance, potency testing and beyond-use dating.

Facility quality is the dominant variable and cannot be assessed from a website.

Ask for the certificate of analysis on the lot. A serious facility has one.